Novo Nordisk is waging a “Price war” on diet pills in the United States, the Associated Press reported. The Novo Nordisk announced that its out-of-pocket prices for Wegovy and Ozempic products in the US had fallen to $349 a month, down 30% from $499 a month, and that as of March 31,2026 American patients receive a limited-time discount of $199 per dose for the first two months of treatment.
Novo Nordisk officials estimate that about 40m Americans will receive their drugs through the expansion of Medicaid and Medicare.
Obesity drugs such as zebound and WEGOTY have become more popular in recent years, the report said. These drugs, known as GLP-1 receptor agonists, work by targeting gut and brain hormones that affect appetite and satiety. In clinical trials, they help people lose 15 to 22 percent of their body weight, and for many people up to 50 pounds or more.
But the report also notes that affordability has been a constant challenge, with a recent survey by the nonprofit organization KFF showing that about half of those taking these treatments say they have difficulty paying for them. Stacy Dussetina, a professor at the Center for Vanderbilt University Medicine, also said studies have shown that when drug costs exceed $100 a month, people struggle to pay for them.